Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high- dose factor VIIa in hemophilia [see comments]
Authors:
Open Access
- 1 January 1994
- journal article
- Published by American Society of Hematology in Blood
- Vol. 83 (1) , 38-42
Abstract
High doses of recombinant factor VIIa are useful in managing bleeding in hemophiliacs with inhibitors. Whether this therapeutic effect of factor VIIa is dependent on tissue factor (TF) is a matter of debate. We examined the ability of freshly isolated human monocytes (which lack TF) to support the activation of coagulation-factor X by factor VIIa. The rate of factor-X activation by factor VIIa was accelerated in the presence of monocytes compared with the rate of X activation in solution. This activation of factor X on monocytes was saturable with a K1/2 of about 400 to 600 pmol/L factor VIIa. The rate of activation was not inhibited by an excess of inhibitory anti-TF antibody or a Gla- containing fragment of prothrombin. In contrast to monocytes, an endothelial cell line did not support activation of factor X by factor VIIa. Our findings suggest that at least one cell type can accelerate activation for factor X by factor VIIa in the absence of TF. This activity requires higher concentrations of factor VIIa than does the TF mechanism. The concentrations of VIIa required are of a similar order of magnitude to those required for a therapeutic effect of VIIa in bleeding hemophiliacs with inhibitors.Keywords
This publication has 6 references indexed in Scilit:
- Management of Hemophilia Patients with InhibitorsHematology/Oncology Clinics of North America, 1992
- A human factor VIIa concentrate and its effects in the hemophilic a dogThrombosis Research, 1989
- Stability of the thrombin-thrombomodulin complex on the surface of endothelial cells from human saphenous vein or from the cell line EA.hy 926Biochemical Journal, 1989
- Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.Proceedings of the National Academy of Sciences, 1989
- Inhibition of prothrombin activation by factor X and factor IX Gla-peptidesBiochemical and Biophysical Research Communications, 1988
- Comparison of lipid binding and kinetic properties of normal, variant, and .gamma.-carboxyglutamic acid modified human factor IX and factor IXaBiochemistry, 1985